Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
UroGen Pharma Ltd
URGN | US
24.31
USD-1.75
-6.72%
URGN | US
About UroGen Pharma Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
23/04/2026
Close
24.31
Open
26.22
High
26.55
Low
23.78
UroGen Pharma Ltd. a biotechnology company engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop make use sell import and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton New Jersey.
View LessURGN | US
Risk
71.2
Sharpe
1.20
Luna's Score
40/100
Recommendation
Sell
Luna says (URGN | US)
What's Working
Positive Momentum
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
84.5%1 month
71.2%3 months
64.1%6 months
72.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
17.69
Debt to equity
3.27
Debt to assets
0.35
Ent. to EBITDA
-2.63
Ent. to rev.
4.63
PEG
-
Other Fundamentals
EBITDA
-78.62M
MarketCap
1.02B
MarketCap(USD)
1.02B
Div. yield
-
Op. margin
-118.27
Erngs. growth
-
Rev. growth
3.40
Ret. on equity
-1.48K
Short ratio
13.09
Short perc.
17.19
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
9.04
Range1M
11.24
Range3M
11.24
Volumes: Market Activity
Rel. volume
1.16
Price X volume
22.54M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.63 | - | Cheaper |
| Ent. to Revenue | 4.63 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 17.69 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 64.10 | - | Par |
| Debt to Equity | 3.27 | -1.23 | Expensive |
| Debt to Assets | 0.35 | 0.25 | Expensive |
| Market Cap | 1.02B | - | Emerging |
